Smith–Magenis syndrome
(Redirected from Chromosome 17p11.2 deletion syndrome)
A genetic disorder characterized by developmental delay and behavioral problems
Smith–Magenis syndrome | |
---|---|
Synonyms | N/A |
Pronounce | N/A |
Specialty | N/A |
Symptoms | Developmental delay, sleep disturbances, behavioral problems |
Complications | N/A |
Onset | Congenital |
Duration | Lifelong |
Types | N/A |
Causes | Deletion or mutation of the RAI1 gene |
Risks | N/A |
Diagnosis | Genetic testing |
Differential diagnosis | N/A |
Prevention | N/A |
Treatment | Symptomatic management |
Medication | N/A |
Prognosis | N/A |
Frequency | 1 in 15,000 to 25,000 births |
Deaths | N/A |
Smith–Magenis syndrome (SMS) is a complex developmental disorder that affects multiple organ systems. It is primarily characterized by distinctive facial features, developmental delay, sleep disturbances, and behavioral problems. SMS is caused by a deletion or mutation of the RAI1 gene on chromosome 17.
Presentation
Individuals with Smith–Magenis syndrome often present with a variety of symptoms that can vary in severity. Common features include:
- Developmental delay: Most children with SMS experience delays in reaching developmental milestones such as sitting, walking, and talking.
- Behavioral problems: These can include self-injurious behaviors, aggression, and temper tantrums. A characteristic feature is the "self-hugging" behavior.
- Sleep disturbances: Individuals with SMS often have an inverted circadian rhythm, leading to sleep problems such as difficulty falling asleep and frequent nighttime awakenings.
- Distinctive facial features: These may include a broad, square-shaped face, deep-set eyes, and a prominent jaw.
- Other features: Short stature, scoliosis, and hearing loss are also common.
Genetics
Smith–Magenis syndrome is typically caused by a deletion of a small piece of chromosome 17, specifically 17p11.2, which includes the RAI1 gene. In some cases, a mutation in the RAI1 gene itself can cause the syndrome. The RAI1 gene is believed to play a crucial role in the development of the nervous system and the regulation of circadian rhythms.
Diagnosis
Diagnosis of Smith–Magenis syndrome is confirmed through genetic testing, which can identify the deletion or mutation of the RAI1 gene. Clinical features and family history are also considered in the diagnostic process.
Management
There is no cure for Smith–Magenis syndrome, and treatment is focused on managing symptoms and improving quality of life. This may include:
- Behavioral therapy: To address behavioral issues and improve social skills.
- Educational support: Special education services tailored to the individual's needs.
- Sleep management: Strategies to improve sleep patterns, which may include melatonin supplements or other medications.
- Medical interventions: For associated conditions such as scoliosis or hearing loss.
Prognosis
The prognosis for individuals with Smith–Magenis syndrome varies. With appropriate support and interventions, many individuals can lead fulfilling lives, although they may require lifelong assistance.
Epidemiology
Smith–Magenis syndrome is estimated to occur in 1 in 15,000 to 25,000 births. It affects both males and females equally and has been reported in various ethnic groups.
History
Smith–Magenis syndrome was first described in 1986 by Ann C. M. Smith and Ellen Magenis, who identified the chromosomal deletion associated with the disorder.
Also see
Genetic disorders relating to deficiencies of transcription factor or coregulators | ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Developmental disorders | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
This developmental disorders related article is a stub.
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD